1. Home
  2. SGN vs CDT Comparison

SGN vs CDT Comparison

Compare SGN & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Signing Day Sports Inc.

SGN

Signing Day Sports Inc.

HOLD

Current Price

$0.17

Market Cap

2.4M

Sector

N/A

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.22

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGN
CDT
Founded
2019
2019
Country
United States
United States
Employees
9
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.8M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
SGN
CDT
Price
$0.17
$1.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
29.7M
113.0K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$366,344.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$1.20
52 Week High
$7.24
$700.68

Technical Indicators

Market Signals
Indicator
SGN
CDT
Relative Strength Index (RSI) 24.45 34.45
Support Level $0.11 $1.30
Resistance Level $0.19 $1.59
Average True Range (ATR) 0.10 0.12
MACD -0.02 0.00
Stochastic Oscillator 9.56 1.28

Price Performance

Historical Comparison
SGN
CDT

About SGN Signing Day Sports Inc.

Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: